Ann: Quarterly Update and Appendix 4C - quarterly, page-3

...Quarterly, some good outlook points, yes mainly covered in AGM but good to see wrap anyway, good to see ongoing conferences in the background (MPS) continuing....



OUTLOOK

• Paradigm expects to complete 100% recruitment in the PARA_OA_008 during 1H 2022.
The program is recruiting and treating at two sites across Australia with top-line data
expected Q3 CY2022.

• Paradigm will present at the WORLD Symposium in San Diego, California, the annual
research conference focused on new therapies for lysosomal storage diseases such as
MPS VI. The presentation will be conducted by leading geneticist and principal
investigator Dr Roberto Giugliani on Paradigm’s phase 2 trial for mucopolysaccharidosis
type-VI (MPS VI). The Company during the conference will release a MPS VI patient focus
group study. The study is the largest of its kind in the world and has attracted the interest
of medical researchers and MPS patient advocacy groups globally.

• Paradigm recently reported the first participant dosing in Australia in the PARA_OA_002
clinical trial. Eight sites have been initiated in Australia and are currently screening
subjects. Initiation of sites in the US continues to ramp up with 65 sites identified in the
US and AUS to participate in the clinical program. The Company expects to report first
participant dosing in the US during Q1 CY 2022.

• The Company expects to continue initiation activities for the PARA_OA_002 clinical study
sites in the UK and Europe and will update shareholders on key activities as they are
achieved.

• The Paradigm Remuneration and Nominations Committee continues its consultation with
a global executive search firm and meetings with shortlisted candidates with the
identified experience in the global pharma industry. The market will be notified on
Identification of the CEO.

• The peer review publication of the company's Phase 2b study (PARA_005) in knee OA is
planned to coincide with publication of ongoing PARA_008. Topline data of PARA-005
have been previously announced in company presentations.

• An Expanded Access Program protocol (EAP) in the US for re-treatment of Zilosul® is being
designed following discussions with the participants and their physician who have
expressed strong interest in a follow-up retreatment program approximately 18 months
following their initial treatment.